XVIVO Perfusion

Valuation Analysis

About the Company

XVIVO Perfusion en bref

XVIVO Perfusion (XVIVO.ST) is currently trading at 252,80 € with a market capitalization of 6,9 Md €. The trailing P/E ratio stands at 107.57x, with a forward P/E of 42.77x. The 52-week range spans from 160,00 € to 310,40 €; the current price is 18.6% below the yearly high. Year-over-year revenue growth stands at +10.2%. The net profit margin stands at 8.85%.

💰 Dividende

XVIVO Perfusion currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent XVIVO Perfusion (XVIVO.ST) au consensus : Achat Fort. L'objectif de cours moyen est de 350,00 €, soit un potentiel de +38.45% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 320,00 € à 385,00 €.

XVIVO Perfusion : la thèse d'investissement en détail

XVIVO Perfusion (XVIVO.ST) operates in the Healthcare — specifically Medical Devices — and is headquartered in Sweden. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 73.11%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 38.45% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 58.56x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 42.77x is meaningfully below the trailing 107.57x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 38.45% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy XVIVO Perfusion?

Compare top-rated brokers — low fees, trusted providers, fully regulated.